Monthly Archives: December 2012

Celebrating 2012’s High Innovation Quotient Deals
December 21, 2012

Innovation paid dividends in 2012.  We often debate the relative “innovation quotient” of the companies we evaluate and invest in here at Atlas, and of the biomedical sector as a whole. The basic premise we hold is that high innovation


The Entrepreneurial Diaspora Enabled By Biotech M&A
December 18, 2012

The recycling of equity capital through realized returns is a critically important element of biotech investing.  When public biotech companies get bought, like Genentech by Roche, or smaller deals like Cougar by J&J, a large number of biotech-focused equity funds


Unleashing Biotech Innovation With The Currency of Entrepreneurship
December 5, 2012

The translation of cutting-edge science into new clinically-relevant therapeutics is the ultimate goal of many academic investigators, industry researchers, and investors.  This stage of R&D is the most challenging, and typically frought with scientific and technical risks: taking a new